Soybean Isoflavones in Bone Health

National Institute of Health and Nutrition, Tokyo, Japan.
Forum of nutrition 02/2009; 61:104-16. DOI: 10.1159/000212743
Source: PubMed

ABSTRACT Soybean isoflavones are structurally similar to estrogen, bind to estrogen receptors, and exhibit weak estrogenic activity. It has been reported that isoflavones play an important role in the prevention of hormone-dependent diseases, including osteoporosis, cardiovascular diseases, cancer, and postmenopausal syndrome. There are many researches indicating isoflavones prevent bone loss caused by estrogen deficiency in animal models. Furthermore, it has been demonstrated that a combination of isoflavone treatment and exercise cooperatively prevented bone loss in the estrogen-deficient status. Epidemiological studies demonstrated the relationship between the lower incidence of osteoporosis in Asian women and a diet rich in soy foods. Although a number of observational studies confirm the findings from the animal studies, the results from intervention studies are still controversial. One of the potential reasons for these inconsistencies could be individual differences in the isoflavone metabolism. Recently, it has been suggested that the clinical effectiveness of isoflavones might partly depend on the ability to produce equol, a gut bacterial metabolite of daidzein showing stronger estrogenic activity than the predominant isoflavones. Several candidate bacteria responsible for equol production have been suggested, for example Lactococcus 20-92 strain. From these findings, food factors enhancing equol production have received great deal of attention recently. On the other hand, safety assessment of isoflavones has been conducted by the Japanese Food Safety Commission. Further studies are required to address the numerous questions on the potential benefits, mechanisms of action, and safety of isoflavones.

1 Bookmark
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background/objectives:Studies have observed associations between the gut microbiome and obesity. O-desmethylangolensin (ODMA) and equol are gut bacterial metabolites of daidzein, a compound found in high amounts in soy foods. Approximately 80-95% and 25-60% of individuals harbor gut microbial communities capable of producing ODMA or equol, respectively. Given that other phenotypes of gut bacterial metabolism of dietary compounds have been associated with obesity, we hypothesized that daidzein-metabolizing phenotypes would be associated with obesity. The objective of this study was to compare the prevalence of ODMA-producer and equol-producer phenotypes in obese, overweight and normal-weight individuals.Subjects/methods:Adults aged 18-95 years (n=297) provided a first-void urine sample after a 3-day soy challenge, and urinary ODMA and equol concentrations were used to classify individuals as producers or non-producers. Body mass index was calculated from self-reported weight and height.Results:There were 60 ODMA non-producers and 173 equol non-producers. Obese individuals were 2.8 times more likely to be ODMA non-producers (odds ratio (OR)=2.8, 95% confidence interval (CI): 1.2, 6.2) compared with normal-weight individuals, when adjusted for age, race (white vs non-white), and gender and menopausal status (male, premenopausal female and postmenopausal female). Obesity was not associated with equol-producer phenotype (OR=1.1, 95% CI: 0.5, 2.2). Stronger associations with obesity were observed in the ODMA non-producers who were also equol producers than in the equol non-producers.Conclusions:Results from this analysis suggest that the ODMA-producer phenotype, but not equol-producer phenotype, is associated with obesity in adults. These results support further work to replicate these findings and evaluate the mechanisms of the observed associations.European Journal of Clinical Nutrition advance online publication, 26 February 2014; doi:10.1038/ejcn.2014.23.
    European journal of clinical nutrition 02/2014; DOI:10.1038/ejcn.2014.23 · 3.07 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We examined the effects of heptamethoxyflavone (HMF), a citrus flavonoid on inflammatory bone resorption. HMF suppressed the osteoclast formation and PGE2 production induced by IL-1. In mouse calvarial organ cultures, HMF attenuated the bone resorption elicited by LPS. HMF suppressed bone resorption in the mandibular alveolar bone. HMF may protect against inflammatory bone loss such as periodontal disease.
    Bioscience Biotechnology and Biochemistry 08/2014; DOI:10.1080/09168451.2014.952616 · 1.27 Impact Factor
  • Source